Skip to main content
AXSM logo

Axsome Therapeutics, Inc. (AXSM) Stock: Price, Forecast & Analyst Target

Axsome Therapeutics, Inc. (AXSM) — MoonshotScore 34/100 (Weak band), calculated Nov 18, 2026. Price $135.68 (+1.25%), as of the Nov 19, 2026 trading session; market cap $7.14B. Expected results Feb 22, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 22.75× (cash as of Sep 30, 2026) · expected results Feb 22, 2027

$135.68 +$1.68 (+1.25%) Market Cap $7.14B

Axsome Therapeutics, Inc. · AXSM · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Axsome Therapeutics is a commercial biopharmaceutical company selling central nervous system medicines while advancing a broad clinical pipeline across depression, migraine, sleep disorders, pain and neuropsychiatric conditions. The case depends on whether product revenue can outgrow the commercial and research spending that still keeps the business unprofitable and usually cash consumptive.

Price as of Nov 19, 2026

Key Statistics

34 of 100

MoonshotScore v2 · Axsome Therapeutics (AXSM)

Weak
Business Quality Solid (61)
Financial Safety Okay (42)
Valuation Full (44)
Growth Durability Growing (64)
Momentum Quiet (41)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A full valuation, though the balance sheet is only middling. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Quiet.

  • quarterly revenue $171M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 3 of the last 8 reports
  • Altman Z 4.27 · Piotroski F 3

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for AXSM (57 recorded, newest six shown)
RecordedScoreBand
34Weak
34Weak
34Weak
34Weak
34Weak
34Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$135.68
Change on the day+1.25%
52-week range$123.00–$260.19
Market capitalisation$7.14B—
Price / earnings (trailing)39.83
Shares traded on the day639.7K
Beta (volatility vs the S&P 500)0.6

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $128, high $255, latest $136. 4 reported quarters marked, 1 above and 3 below the recorded estimate. $255 $128 high $255 Feb 23, 2026 · Earnings results · reported below the recorded estimate · close $1841May 4, 2026 · Earnings results · reported below the recorded estimate · close $2072Aug 10, 2026 · Earnings results · reported below the recorded estimate · close $2133Nov 2, 2026 · Earnings results · reported above the recorded estimate · close $1444 Oct 17, 2025 Nov 19, 2026 · $136 $128Oct 17, 2025$135Oct 31, 2025$140Nov 14, 2025$152Nov 28, 2025$148Dec 12, 2025$152Dec 26, 2025$169Jan 9, 2026$186Jan 23, 2026$183Feb 6, 2026$184Feb 20, 2026$162Mar 6, 2026$157Mar 20, 2026$169Apr 2, 2026$189Apr 17, 2026$207May 1, 2026$228May 15, 2026$234May 29, 2026$255Jun 12, 2026$242Jun 26, 2026$234Jul 10, 2026$241Jul 24, 2026$213Aug 7, 2026$208Aug 21, 2026$207Sep 4, 2026$208Sep 18, 2026$179Oct 2, 2026$157Oct 16, 2026$144Oct 30, 2026$142Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Axsome Therapeutics (AXSM): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Neutral
Valuation Neutral
Growth Durability Moderate
Momentum Neutral

Legends Council

2 lenses, 2 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Axsome Therapeutics (AXSM), and what does it report?

Short answer · as of

Axsome is no longer simply a clinical-stage biotechnology developer.

Reported revenue comes from product sales, while its development portfolio seeks additional uses and treatments across central nervous system disorders.

The financial statements therefore capture two businesses at once: a commercial operation building product demand and a research organization funding late-stage programs. Revenue has expanded sharply, but selling and administrative expense now outweighs research spending by a wide margin, making commercial efficiency increasingly important.

2 · Latest results

What do the latest results show for Axsome Therapeutics (AXSM)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $171M.

The latest period brought renewed sequential revenue growth, higher gross profit and narrower operating and net losses. Revenue reached the strongest level in the reported quarterly series after a brief pullback, extending the substantial expansion visible in the annual record.

The improvement was not yet clean. Selling and administrative expense continued to climb, operating cash outflow worsened, and the latest reported revenue and loss both fell short of consensus. Higher gross profit and lower research expense helped the accounting loss narrow despite the heavier commercial cost base.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$259.69M Sep 30, 2026
Latest quarter · R&D
$50.62M Sep 30, 2026
Latest quarter · SG&A
$203.11M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$11.07M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$259.69M$50.62M$203.11M−$11.07M
Jun 30, 2026$218.38M$46.23M$208.14M−$49.65M
Mar 31, 2026$191.20M$52.68M$185.00M−$63.36M
Dec 31, 2025$196.00M$48.79M$169.30M−$29.43M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$259.69M Nov 2, 2026
Latest report · revenue estimate
$249.19M Nov 2, 2026
Latest report · revenue vs estimate
Above estimate Nov 2, 2026
Latest report · EPS vs estimate
Above estimate Nov 2, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 2, 2026$259.69M$249.19M−$0.2500−$0.6342
Aug 10, 2026$216.35M$221.11M−$0.9900−$0.8921
May 4, 2026$189.40M$190.91M−$1.2600−$0.8500
Feb 23, 2026$194.69M$193.36M−$0.7100−$0.7000
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$171M-$47M-$0.94 (diluted)
Q4 FY2025$196M-$29M-$0.56 (diluted)
Q1 FY2026$191M-$65M-$1.26 (diluted)
Q2 FY2026$218M-$51M-$0.99 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Axsome Therapeutics (AXSM)?

Short answer

Cash and short-term investments were $313.86M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$9.47M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.

Liquidity exceeds total debt, leaving Axsome with net cash, and the cash balance has remained within a relatively narrow band across the reported window despite operations consuming cash in most periods. That provides room to fund commercialization and clinical work without an immediate balance-sheet constraint.

The risk sits in the conversion of growth into durable cash generation. Gross margins are high, but selling and administrative spending is rising rapidly, operating losses persist, and the market value stands far above the net cash position. A slowdown in product revenue without a matching adjustment in spending would pressure both the valuation case and the financial cushion.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
  • Rich valuation — a P/E of 39.83 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
−$9.47M Sep 30, 2026
Previous quarter · operating cash flow
−$32.95M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026−$9.47M−$200,000
Jun 30, 2026−$32.95M−$450,000
Mar 31, 2026−$20.70M−$120,000
Dec 31, 2025−$18.65M−$70,000
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Axsome Therapeutics (AXSM)?

Short answer · as of

The next earnings report is expected on Feb 22, 2027.

The upcoming earnings report needs to be read through three linked observations: whether revenue accelerates as consensus expects, whether the loss contracts, and whether operating cash flow begins to follow the improvement in the income statement. Revenue growth accompanied by another sharp increase in commercial expense would be less persuasive than growth that narrows losses and reduces cash use.

Clinical progress also matters because Axsome’s expansion path reaches beyond current product sales. Updates involving depression, Alzheimer’s disease agitation, smoking cessation, migraine, narcolepsy or fibromyalgia could change the breadth of the future portfolio, while delays would leave more of the burden on the existing commercial business.

What the records here don't tell us

  • The newest quarter held here (Q3 FY2025) was filed Nov 3, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Axsome Therapeutics compare with its peers?

Short answer

Axsome Therapeutics's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Axsome differs from a pre-revenue biotechnology developer because product sales already form a substantial and rapidly expanding business. It also differs from a mature specialty pharmaceutical company because continuing losses and a broad late-stage central nervous system pipeline still make research execution and financing discipline central to the story.

That combination produces attractive product gross margins but heavy commercial and development spending. Comparable businesses may depend mainly on trial outcomes or mainly on established brands; Axsome must prove that its commercial platform can fund continued portfolio expansion.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.82 Nov 19, 2026$9.36B96 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$19.50 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$124.39 Nov 19, 2026$5.25B66 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$156.23 Nov 18, 2026$6.35B64 5-pillar Nov 18, 2026
Jazz Pharmaceuticals plc (JAZZ) Named competitor$247.77 Nov 18, 2026$15.9B40 5-pillar Nov 18, 2026
Axsome Therapeutics (AXSM) — this page$135.68$7.14B34
Arrowhead Pharmaceuticals, Inc. (ARWR) Named competitor$43.65 Nov 19, 2026$6.17B12 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$238.00 – $380.00
Consensus target
$279.25
Median target
$267.50

Consensus record · Captured .

Measured against a quoted price of $135.68 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 3, 2026

Transactions
38
Identified insiders
7
Purchases
0
Sales
14
Other transactions
24

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
77.7% Period end Sep 30, 2026
Previous quarter · ownership
75.3% Prior to period end Sep 30, 2026
Reporting holders
490 Period end Sep 30, 2026
Previous quarter · holders
542 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.3,451,847
Vanguard Capital Management LLC2,007,061
Vanguard Portfolio Management LLC1,972,645
Invesco Ltd.1,930,336
Fmr LLC1,444,439

Tracked investors

Which of the 16 named investors we follow held AXSM in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.10%$23.20MAdded +116.1% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Axsome Therapeutics (AXSM)?

Read these with our analysis →

Axsome Therapeutics Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

What does Axsome actually sell while its CNS pipeline advances?

Reported revenue comes from product sales, while the company continues developing treatments across several central nervous system disorders. Its results therefore reflect active commercialization alongside clinical research rather than research spending alone.

Why did Axsome’s latest accounting loss narrow as cash use increased?

Higher gross profit and lower research expense more than offset the rise in selling and administrative spending, narrowing the reported loss. Operating cash outflow nevertheless increased, so the income-statement improvement had not yet translated into stronger cash generation.

Can Axsome’s cash position carry its late-stage CNS programs?

Liquidity exceeds debt and cash has been broadly stable across the reported span, providing a meaningful cushion. Operations still consume cash in most periods, so the durability of that cushion depends on product growth eventually producing sustained operating cash.

Which disorders could expand Axsome beyond its current product revenue?

The development portfolio spans depression, treatment-resistant depression, Alzheimer’s disease agitation, smoking cessation, migraine, narcolepsy and fibromyalgia. Progress across those programs could broaden the commercial base beyond the products generating revenue now.

What is the AXSM stock price today?

The last price recorded for Axsome Therapeutics, Inc. (AXSM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the AXSM price target?

The analyst consensus price target for Axsome Therapeutics, Inc. (AXSM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 80 figures on this page — 1 from SEC filings and earnings calls, 72 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 1. What is Axsome Therapeutics (AXSM), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Axsome Therapeutics (AXSM)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Trailing twelve-month ratio set
  • 3. What are the financial strengths and risks for Axsome Therapeutics (AXSM)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Operating cash flow by quarter (USD millions); Cash against market value; Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • 4. What should you watch next at Axsome Therapeutics (AXSM)?: Next earnings report; Reported versus estimated, last 8 quarters; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Business description
  • 5. How does Axsome Therapeutics compare with its peers?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • FAQ: What does Axsome actually sell while its CNS pipeline advances?: Revenue by segment; Business description; Quarterly income statement (USD thousands)
  • FAQ: Why did Axsome’s latest accounting loss narrow as cash use increased?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • FAQ: Can Axsome’s cash position carry its late-stage CNS programs?: Cash, investments and debt; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Operating cash flow by quarter (USD millions); Business description
  • FAQ: Which disorders could expand Axsome beyond its current product revenue?: Business description; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold AXSM

Funds in our ETF coverage that list AXSM among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Neuroscience and Healthcare ETF (IBRN)4.53%